In the UK a government initiative has funneled a small amount of cash into two organizations—Chief.AI and the Medicines Discovery Catapult—in an effort to make AI accessible to all drug discovery researchers and help nudge the UK bioscience sector into the future. It amounts to just £370,000 which “will address the need for more accessible AI and data in the B2B marketplace—prioritising drug discovery, diagnostics and clinical trials markets.” Source: Fierce Biotech 7/52019